» Articles » PMID: 34330186

What is the Gold Standard Model for Alzheimer's Disease Drug Discovery and Development?

Overview
Specialties Chemistry
Pharmacology
Date 2021 Jul 31
PMID 34330186
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease models (ADMs) are currently used for drug development (DD). More than 20,000 molecules were screened for AD treatment over decades, with only one drug (Aducanumab)FDA-approved over the past 18 years. A revision of pathogenic concepts and ADMs are needed. The authors discuss herein preclinical models including: (i) in vitro models (cell lines, primary neuron cell cultures, iPSC-derived brain cells), (ii) ex vivo models, and (iii) in vivo models (artificial, transgenic, non-transgenic and induced). The following types of ADMs have been reported: Mouse models (45.08%), Rat models (15.04%), Non-human Primate models (0.76%), Rabbit models (0.46%), Cat models (0.53%), Pig models (0.30%), Guinea pig models (0.15%), models (0.02%), Dog models (0.54%), models (1.79%), Zebrafish models (0.50%), (1.21%), Cell culture models (3.31%), Cholinergic models (8.26%), Neurotoxic models (6.79%), Neuroinflammation models (6.92%), Neurovascular models (7.88%), and Microbiome models (0.45%).No single ADM faithfully reproduces all the pathogenic events in the human AD phenotype spectrum. ADMs should be different for (i) pathogenic studies vs basic DD, and (ii) preventive interventions vs symptomatic treatments. There cannot be an ideal ADM for DD, because AD is a spectrum of syndromes. DD can integrate pathogenic, mechanistic, metabolic, transporter and pleiotropic genes in a multisystem model.

Citing Articles

Therapeutic Options in Alzheimer's Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity.

Cacabelos R, Martinez-Iglesias O, Cacabelos N, Carrera I, Corzo L, Naidoo V Life (Basel). 2025; 14(12.

PMID: 39768263 PMC: 11678002. DOI: 10.3390/life14121555.


From network pharmacology to molecular docking analysis of sterubin targets for Alzheimer.

Viswanathan S, Arumugam T, Sivaraj R, Subhashri Rajendran S, Ramesh V, Subramanian K Bioinformation. 2024; 20(4):327-336.

PMID: 38854763 PMC: 11161872. DOI: 10.6026/973206300200327.


Oral Administration of Leaf Extract Ameliorates Alzheimer's Disease Phenotypes in 5xFAD Transgenic Mice.

Kim Y, Cho M, Jang C, Lee J, Kim J, Oh J Foods. 2024; 13(5).

PMID: 38472795 PMC: 10930996. DOI: 10.3390/foods13050682.


Vitamin B12 Attenuates Changes in Phospholipid Levels Related to Oxidative Stress in SH-SY5Y Cells.

Theiss E, Griebsch L, Lauer A, Janitschke D, Erhardt V, Haas E Cells. 2022; 11(16).

PMID: 36010649 PMC: 9406929. DOI: 10.3390/cells11162574.


Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer's Disease.

Martinez-Iglesias O, Naidoo V, Carrera I, Cacabelos R Int J Mol Sci. 2022; 23(5).

PMID: 35269588 PMC: 8909965. DOI: 10.3390/ijms23052446.